Drug Approval | November 17, 2025
EMA recommends authorization of Teizeild to delay Type 1 diabetes onset
This is the first drug to receive a recommendation for this preventative indication in the European Union
This is the first drug to receive a recommendation for this preventative indication in the European Union
Cardiovascular disease (CVD) is the leading cause of death in the US and worldwide with over 82 million Americans living with CVD
Relmada expects to initiate its Phase 3 program in the first half of 2026
The ALLEGORY study demonstrated statistically significant improvements in key measures, including British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
Building on the Merck Foundation’s longstanding commitment to advancing access to high-quality health care, new national initiative supports grants to 11 organizations across the country
ADX-248, which replaces ADX-743, is being developed for the treatment of metabolic inflammation, including obesity and hypertriglyceridemia
The FDA’s review also revealed delays in Philips’ internal investigations, with 54 inquiries failing to meet targeted completion dates—23 of which were delayed by more than 100 days
Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body
Basketball legend, entrepreneur, and entertainer Shaquille O’Neal partners with Lilly to encourage Americans to recognize the signs of obstructive sleep apnea and talk to their
Subscribe To Our Newsletter & Stay Updated
